A few weeks after Beren Therapeutics received word from the U.S. Food and Drug Administration that it would delay a decision on its rare-disease drug candidate, the company announced it has been working to secure funding in the meantime. Based in Thousand Oaks, Beren Therapeutics announced on June 10 that it has secured $300 million…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
